IgG2 Galactosylation is related to higher antibody dependent enhancement for dengue in cross-reactive antibodies from Sars-CoV-2
Reinig, S.; Chin, K.; Shih, S.-R.
Show abstract
Cross-reactive antibodies against dengue virus are known to cause antibody-dependent enhancement (ADE) of infection or disease severity under specific conditions. In our previous study, we showed that primary immunization with the COVID-19 vaccine induces induces cross-reactive IgG causing ADE against dengue. In the present study, we investigated the influence of IgG Fc-glycosylation (analyzed by LC-MS/MS) on ADE mediated by cross-reactive IgG against dengue from IgG against SARS-CoV-2. We found a clear correlation between anti-DENV2 E IgG2 galactosylation and the ADE capacity of cross-reactive IgG against dengue in individuals vaccinated against COVID-19. IgG2 sialylation increased over time; however, it was not correlated with ADE capacity. This phenomenon was restricted to IgG2, whereas anti-DENV2 E IgG1 Fc-glycosylation remained stable after COVID-19 vaccination.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: A 9 months longitudinal study 94%
- Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals 94%
- XBB.1.5 Spike Protein COVID-19 Vaccine Induces Broadly Neutralizing and Cellular Immune Responses Against EG.5.1 and Emerging XBB Variants 93%
Similar papers in this journal
- Immune response after SARS-CoV-2 infection with residual post COVID symptoms 94%
- The effect of waning on antibody levels and memory B cell recall following SARS-CoV-2 infection or vaccination 94%
- Mice immunized with the vaccine candidate HexaPro spike produce neutralizing antibodies against SARS-CoV-2 94%
Similar papers in this journal
- PF-D-Trimer, a broadly protective SARS-CoV-2 subunit vaccine: immunogenicity and application 95%
- mRNA-based vaccine candidate COReNAPCIN(R) induces robust humoral and cellular immunity in mice and non-human primates 93%
- Multivalent administration of dengue E dimers on liposomes elicits type-specific neutralizing responses without immune interference 93%
Similar papers in this journal
- Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine 92%
- Elite neutralizers of human cytomegalovirus are characterized by high magnitude plasma IgG responses against multiple glycoprotein complexes 92%
- SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity 92%
Similar papers in this journal
- Antibody response after a single dose of BBV152 vaccine negatively correlates with pre-existing antibodies and induces a significant but low levels of neutralizing antibodies to Omicron variant 95%
- The association of neutralizing antibodies with protection against symptomatic dengue virus infection varies by serotype, prior infection history, and assay condition 94%
- A Gamma-adapted recombinant subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection. 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.